Literature DB >> 12888777

Harm avoidance, anxiety, and response to novelty in the adolescent S-100beta transgenic mouse: role of serotonin and relevance to Down syndrome.

Kimberly Bell1, David Shokrian, Carl Potenzieri, Patricia M Whitaker-Azmitia.   

Abstract

S-100beta is an astroglial-derived protein, which plays a role in brain development and maintenance, and is known to play a specific role in the regulation of growth of the serotonergic neuronal system. In humans, the gene for S-100beta is found on chromosome 21, within the region that is considered important for the phenotype of Down syndrome (DS). Thus, we have been studying a model of DS, the S-100beta transgenic mouse. In the current study, we have examined anxiety and responses to novelty in adolescent (60-90 days) animals, at a time when we have shown the animals to be relatively lacking in serotonin innervation, compared to their CD-1 nontransgenic controls. In a test for approach/avoidance, the light/dark test, the S-100beta transgenic mice animals showed no differences from control CD-1 mice. However, in the hole-board test for exploratory behavior, the S-100beta animals were found to be less responsive to the inhibiting effects of the serotonin receptor 5-HT1A agonist, buspirone. Three tests were used to measure response to novelty. In the open field, the S-100beta animals showed greater activity longer than the control animals, and in the Y-maze test, the S-100beta animals spent more time in the novel arm. In a test for novelty-induced gnawing, the S-100beta animals were also more active than control animals. All of these suggest that the S-100beta transgenic mice are slower to habituate to novelty than control animals. Finally, we tested the animals in a new procedure that we are proposing as a test for harm avoidance. In this apparatus, the S-100beta animals showed more approaches to a novel and potentially harmful object than the control mice did. These results are discussed in reference to the known lack of serotonin in the animals, and to the behavioral phenotype of DS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888777     DOI: 10.1038/sj.npp.1300242

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  6 in total

1.  Chronic fluoxetine treatment changes S100B expression during postnatal rat brain development.

Authors:  Nathalie Bock; Emre Koc; Hannah Alter; Veit Roessner; Andreas Becker; Aribert Rothenberger; Till Manzke
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-11       Impact factor: 2.576

2.  Neonatal serotonin depletion alters behavioral responses to spatial change and novelty.

Authors:  Christine F Hohmann; Ellen M Walker; Carolyn B Boylan; Mary E Blue
Journal:  Brain Res       Date:  2007-01-17       Impact factor: 3.252

3.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

4.  The S100B/RAGE Axis in Alzheimer's Disease.

Authors:  Estelle Leclerc; Emmanuel Sturchler; Stefan W Vetter
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-21

5.  Beneficial effects of intravenous dexmedetomidine on cognitive function and cerebral injury following a carotid endarterectomy.

Authors:  Ya-Li Ge; Xiaobo Li; J U Gao; Xicheng Zhang; Xiangzhi Fang; Luojing Zhou; Wei Ji; Shunyan Lin
Journal:  Exp Ther Med       Date:  2016-01-11       Impact factor: 2.447

6.  Partial Monosomy 21 Mirrors Gene Expression of Trisomy 21 in a Patient-Derived Neuroepithelial Stem Cell Model.

Authors:  Jakob Schuy; Jesper Eisfeldt; Maria Pettersson; Niloofar Shahrokhshahi; Mohsen Moslem; Daniel Nilsson; Niklas Dahl; Mansoureh Shahsavani; Anna Falk; Anna Lindstrand
Journal:  Front Genet       Date:  2022-02-04       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.